Current management of age-related macular degeneration (AMD) can be divided into two categories: first, anti-vasoendothelial growth factor (anti-VEGF) injection for wet macular degeneration; second, anti-oxidant vitamins for dry macular degeneration. New therapies are being developed for both of these diseases using novel technologies and different modes of administration. The hope is that some of these therapies will achieve significant improvement to current management and prevent future loss of vision in this devastating eye condition. © 2014 Faculty of 1000 Ltd.
CITATION STYLE
Singer, M. (2014). Advances in the management of macular degeneration. F1000Prime Reports, 6. https://doi.org/10.12703/P6-29
Mendeley helps you to discover research relevant for your work.